| TAMSULOSIN HYDROCHLORIDE (tam'su-lo-sin)
 Flomax
 Classifications: alpha-adrenergic antagonist;  Therapeutic: smooth muscle relaxant of bladder outlet & prostate gland
 Prototype: Prazosin HCl
 Pregnancy Category: B
 
 | 
 
 
 
 Availability
 
 0.4 mg capsules
 
 Action
 
 Antagonist of the alpha1A-adrenergic receptors located in the prostate. Blockage of alpha1A-adrenergic receptors can cause smooth muscles in the bladder outlet and the prostate gland to relax, resulting in improvement 
 in urinary blood flow and a reduction in symptoms of BPH. 
 
 
 Therapeutic Effect
 
 Effectiveness is indicated by improved voiding. Improves symptoms related to benign prostatic hypertrophy (BPH) related 
 to bladder outlet obstruction. 
 
 
 Uses
 
 Benign prostatic hypertrophy.
 
 Contraindications
 
 Hypersensitivity to tamsulosin; in conjunction with another alpha1A-adrenergic blocking agent; women; lactation, pediatric patients. 
 
 
 Cautious Use
 
 History of syncope, hypersensitivity to sulfonamides; hypotension; older adults; renal impairment, renal failure, renal 
 disease; pregnancy (category B). 
 
 
 Route & Dosage
 
  
  
 | Benign Prostatic Hypertrophy Adult: PO 0.4 mg q.d. 30 min after a meal, may increase up to 0.8 mg q.d.
 
 | 
 
 
 
 
Administration
Oral 
 - Give 30 min after the same meal each day.
- Instruct to swallow capsules whole; not to crush, chew, or open.
- If dose is interrupted for several days, reinitiate at the lowest dose, 0.4 mg.
- Store at 20°25° C (68°77° F).
Adverse Effects (≥1%)
Body as a Whole: Asthenia, back or chest pain. 
CNS: Headache, dizziness, insomnia. 
CV: Orthostatic hypotension (especially with first dose). GI: Diarrhea, nausea. 
Respiratory: Rhinitis, pharyngitis, increased cough, 
sinusitis. 
Urogenital: Decreased libido, 
abnormal ejaculation. Special Senses: Amblyopia. 
 
Interactions
Drug: Cimetidine may decrease clearance of tamsulosin. 
Sildenafil, vardenafil, and 
tadalafil, and 
alcohol may enhance hypotensive effects. 
 
Pharmacokinetics
Absorption: Rapidly from GI tract. >90% bioavailability. 
Peak: 45 h fasting, 67 h fed. 
Distribution: Widely distributed in body tissues, including kidney and prostate. 
Metabolism: In the liver. 
Elimination: 76% in urine. 
Half-Life: 1415 h. 
 
Nursing Implications
 
 Assessment & Drug Effects
 
  
 - Monitor for signs of orthostatic hypotension; take BP lying down, then upon standing. Report a systolic pressure drop of 
 ≥15 mm Hg or a HR ≥15 beats 
 upon standing. 
 
- Monitor patients on warfarin therapy closely.
Patient & Family Education
 
  
 - Make position changes slowly to minimize orthostatic hypotension.
- Report dizziness, vertigo, or fainting to physician. Exercise caution with hazardous activities until response to drug is 
 known. 
 
- Be aware that concurrent use of cimetidine may increase the orthostatic hypotension adverse effect.